Teijin Limited

Akinobu Nakanishi

Tomonori Yokoyama

Yoshiyuki Matsumoto

Susumu Takeuchi

Minoru Imai

Kunio Minamizono

Yoshiyuki Sawai

Takashi Kamimura

Tatsuki Shiota

Masaki Sudoh

Yumiko Muroga

A medicine containing, as an active ingredient, a cyclic amine derivative represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable Cto Calkyl addition salt thereof. The medicine has an action for treating or preventing diseases in which CCR3 participates, such as asthma and allergic rhinitis.

Cyclic amine CCR3 antagonist

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C-Calkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis. 

4,4-disubstituted piperidine derivatives having CCR3 antagonism

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C-Calkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis. 

Piperidine derivatives having CCR3 antagonism

Growing community of inventors

Tokyo, Japan

Akinobu Nakanishi